Roche to Acquire Molecular Diagnostics Firm for $1.8 Billion

March 16, 2021

Roche has entered a definitive agreement to acquire GenMark Diagnostics, a molecular diagnostics maker based in Carlsbad, Calif., for $1.8 billion.

GenMark offers respiratory pathogen panels that identify the most common viral and bacterial organisms associated with upper respiratory infection, including SARS-CoV-2. The company received FDA Emergency Use Authorization (EUA) in October 2020 and a CE mark in September 2020 for a rapid molecular panel that detects more than 20 respiratory pathogens, including the coronavirus.

GenMark also earned an EUA in March 2020 for its ePlex SARS-CoV-2 test, a nasopharyngeal swab diagnostic that automatically provides results in under two hours and can handle up to 96 tests per eight-hour shift in laboratory settings.

The transaction is expected to become final in the second quarter of the year, after which GenMark will continue to operate at its Carlsbad headquarters.

View today's stories